Special Issue "Feature Papers"
Quicklinks
A special issue of Microarrays (ISSN 2076-3905).
Deadline for manuscript submissions: closed (31 December 2012)
Special Issue Editor
Guest Editor
Prof. Dr. Ulrich Certa
Department of Molecular Toxicology, F. Hoffmann-La Roche AG, 4070 Basel, Switzerland
E-Mail: ulrich.certa@roche.com
Phone: +41 61 688 53 40
Interests: pharmacogenomics; drug safety; transcriptional responses to drugs; copy-number variation; deep sequencing; genomic analysis of animal models
Special Issue Information
Dear Colleagues,
This is a collection of top quality papers published free of charge in Open Access form by the editorial board members, or those invited by the editorial office and the Editor-in-Chief. The papers should be long research papers (or review papers) with full and detailed summary of the author's own work done so far.
Prof. Dr. Ulrich Certa
Guest Editor
Submission
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microarrays is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts.
English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
Keywords
- multiplex lab-on-a-chip
- high-throughput screening
- DNA microarrays, cDNA microarrays, oligonucleotide microarrays and SNP microarrays
- MMChips, for surveillance of microRNA populations
- Protein microarrays
- Tissue microarrays
- Cellular microarrays or transfection microarrays
- Chemical compound microarrays
- Antibody microarrays
- Carbohydrate arrays (glycoarrays)
- high throughput sequencing
Published Papers (6 papers)
|
Received: 13 June 2012; in revised form: 13 July 2012 / Accepted: 31 July 2012 / Published: 6 August 2012
Show/Hide Abstract
| Download PDF Full-text (618 KB) | Download XML Full-text
Abstract: Microarrays constitute a new platform which allows the discovery and characterization of proteins. According to different features, such as content, surface or detection system, there are many types of protein microarrays which can be applied for the identification of disease biomarkers and the characterization of protein expression patterns. However, the analysis and interpretation of the amount of information generated by microarrays remain a challenge. Further data analysis strategies are essential to obtain representative and reproducible results. Therefore, the experimental design is key, since the number of samples and dyes, among others aspects, would define the appropriate analysis method to be used. In this sense, several algorithms have been proposed so far to overcome analytical difficulties derived from fluorescence overlapping and/or background noise. Each kind of microarray is developed to fulfill a specific purpose. Therefore, the selection of appropriate analytical and data analysis strategies is crucial to achieve successful biological conclusions. In the present review, we focus on current algorithms and main strategies for data interpretation.
 |
|
Received: 25 June 2012; in revised form: 25 July 2012 / Accepted: 3 August 2012 / Published: 7 August 2012
Show/Hide Abstract
| Download PDF Full-text (889 KB) | Download XML Full-text
Abstract: Quality control and normalization is considered the most important step in the analysis of microarray data. At present there are various methods available for quality assessments of microarray datasets. However there seems to be no standard visualization routine, which also depicts individual microarray quality. Here we present a convenient method for visualizing the results of standard quality control tests using Circos plots. In these plots various quality measurements are drawn in a circular fashion, thus allowing for visualization of the quality and all outliers of each distinct array within a microarray dataset. The proposed method is intended for use with the Affymetrix Human Genome platform (i.e., GPL 96, GPL570 and GPL571). Circos quality measurement plots are a convenient way for the initial quality estimate of Affymetrix datasets that are stored in publicly available databases.
|
|
Received: 28 June 2012; in revised form: 26 July 2012 / Accepted: 7 August 2012 / Published: 8 August 2012
Show/Hide Abstract
| Download PDF Full-text (687 KB) | Download XML Full-text
Abstract: A sandwich microarray employing two distinct aptamers for human thrombin has been optimized for the detection of subnanomolar concentrations of the protein. The aptamer microarray demonstrates high specificity for thrombin, proving that a two-site binding assay with the TBA1 aptamer as capture layer and the TBA2 aptamer as detection layer can ensure great specificity at times and conditions compatible with standard routine analysis of biological samples. Aptamer microarray sensitivity was evaluated directly by fluorescent analysis employing Cy5-labeled TBA2 and indirectly by the use of TBA2-biotin followed by detection with fluorescent streptavidin. Sub-nanomolar LODs were reached in all cases and in the presence of serum, demonstrating that the optimized aptamer microarray can identify thrombin by a low-cost, sensitive and specific method.
|
|
Received: 24 September 2012; in revised form: 31 October 2012 / Accepted: 7 November 2012 / Published: 9 November 2012
Show/Hide Abstract
| Download PDF Full-text (458 KB) | Download XML Full-text
Abstract: This overview describes microarray-based tests that combine solution-phase amplification chemistry and microarray hybridization within a single microfluidic chamber. The integrated biochemical approach improves microarray workflow for diagnostic applications by reducing the number of steps and minimizing the potential for sample or amplicon cross-contamination. Examples described herein illustrate a basic, integrated approach for DNA and RNA genomes, and a simple consumable architecture for incorporating wash steps while retaining an entirely closed system. It is anticipated that integrated microarray biochemistry will provide an opportunity to significantly reduce the complexity and cost of microarray consumables, equipment, and workflow, which in turn will enable a broader spectrum of users to exploit the intrinsic multiplexing power of microarrays for infectious disease diagnostics.
|
|
Received: 27 November 2012; in revised form: 24 January 2013 / Accepted: 26 February 2013 / Published: 5 March 2013
Show/Hide Abstract
| Download PDF Full-text (626 KB) | Download XML Full-text
Abstract: Harmful algal blooms (HABs) occur worldwide, causing health problems and economic damages to fisheries and tourism. Monitoring agencies are therefore essential, yet monitoring is based only on time-consuming light microscopy, a level at which a correct identification can be limited by insufficient morphological characters. The project MIDTAL (Microarray Detection of Toxic Algae)—an FP7-funded EU project—used rRNA genes (SSU and LSU) as a target on microarrays to identify toxic species. Furthermore, toxins were detected with a newly developed multiplex optical Surface Plasmon Resonance biosensor (Multi SPR) and compared with an enzyme-linked immunosorbent assay (ELISA). In this study, we demonstrate the latest generation of MIDTAL microarrays (version 3) and show the correlation between cell counts, detected toxin and microarray signals from field samples taken in Arcachon Bay in France in 2011. The MIDTAL microarray always detected more potentially toxic species than those detected by microscopic counts. The toxin detection was even more sensitive than both methods. Because of the universal nature of both toxin and species microarrays, they can be used to detect invasive species. Nevertheless, the MIDTAL microarray is not completely universal: first, because not all toxic species are on the chip, and second, because invasive species, such as Ostreopsis, already influence European coasts.
|
|
Received: 6 February 2013; in revised form: 18 March 2013 / Accepted: 20 March 2013 / Published: 27 March 2013
Show/Hide Abstract
| Download PDF Full-text (324 KB) | Download XML Full-text
Abstract: The role of gene deletion and duplication in the aetiology of disease has become increasingly evident over the last decade. In addition to the classical deletion/duplication disorders diagnosed using molecular techniques, such as Duchenne Muscular Dystrophy and Charcot-Marie-Tooth Neuropathy Type 1A, the significance of partial or whole gene deletions in the pathogenesis of a large number single-gene disorders is becoming more apparent. A variety of dosage analysis methods are available to the diagnostic laboratory but the widespread application of many of these techniques is limited by the expense of the kits/reagents and restrictive targeting to a particular gene or portion of a gene. These limitations are particularly important in the context of a small diagnostic laboratory with modest sample throughput. We have developed a gene-targeted, custom-designed comparative genomic hybridisation (CGH) array that allows twelve clinical samples to be interrogated simultaneously for exonic deletions/duplications within any gene (or panel of genes) on the array. We report here on the use of the array in the analysis of a series of clinical samples processed by our laboratory over a twelve-month period. The array has proven itself to be robust, flexible and highly suited to the diagnostic environment.
 |
Last update: 12 October 2012
